Combination therapies, whereby two or more defined types of therapies such as surgery, chemotherapy, radiation therapy, etc. are administered together, are often required in order to ensure a synergistic effect at the tumor site. Major pharmacological strategies for cancer management consist in conventional chemotherapy, targeted therapy and immunotherapy. These use drugs, genetic material, antibodies or synthetic proteins to directly kill cancer cells, block mutation-driven signaling pathways or activate the immune system. Despite promising advancements, a significant issue with these anti-cancer strategies is related to poor targeting of tumor cells and toxicity for normal cells. The development of more effective formulations able to deliver multiple agents that act complementarily is thus vital to overcome current limitations. In the last decade it became increasingly clear that nanotechnology has a specific role to play with the design and development of a new generation of delivery formulations based on smart and personalized nanocarriers.
In this context, this Research Topic “Stimuli-responsive nanocarriers: New insights and future perspectives in cancer management” aims to highlight novel modalities, strategies, technologies or smart nanocarrier-based formulations that are modernising cancer therapy. We encourage original research, reviews, perspectives, and case-reports, related to cancer research.
Specific topics may include, but are not limited to:
• Development of smart/stimuli responsive nanocarriers for drug delivery formulations in cancer
• Development of smart/stimuli responsive nanocarriers for gene therapy formulations in cancer
• Development of smart/stimuli responsive nanocarriers for immunotherapy formulations
• Novel strategies for the evaluation of advanced delivery formulation in cancer
• Novel anticancer drugs able to be loaded within nanocarriers
• Development of gut microbiota nanotherapies able to modulate the efficacy of anti-cancer treatment
• In vivo/in vitro models working with delivery formulations in cancer
Combination therapies, whereby two or more defined types of therapies such as surgery, chemotherapy, radiation therapy, etc. are administered together, are often required in order to ensure a synergistic effect at the tumor site. Major pharmacological strategies for cancer management consist in conventional chemotherapy, targeted therapy and immunotherapy. These use drugs, genetic material, antibodies or synthetic proteins to directly kill cancer cells, block mutation-driven signaling pathways or activate the immune system. Despite promising advancements, a significant issue with these anti-cancer strategies is related to poor targeting of tumor cells and toxicity for normal cells. The development of more effective formulations able to deliver multiple agents that act complementarily is thus vital to overcome current limitations. In the last decade it became increasingly clear that nanotechnology has a specific role to play with the design and development of a new generation of delivery formulations based on smart and personalized nanocarriers.
In this context, this Research Topic “Stimuli-responsive nanocarriers: New insights and future perspectives in cancer management” aims to highlight novel modalities, strategies, technologies or smart nanocarrier-based formulations that are modernising cancer therapy. We encourage original research, reviews, perspectives, and case-reports, related to cancer research.
Specific topics may include, but are not limited to:
• Development of smart/stimuli responsive nanocarriers for drug delivery formulations in cancer
• Development of smart/stimuli responsive nanocarriers for gene therapy formulations in cancer
• Development of smart/stimuli responsive nanocarriers for immunotherapy formulations
• Novel strategies for the evaluation of advanced delivery formulation in cancer
• Novel anticancer drugs able to be loaded within nanocarriers
• Development of gut microbiota nanotherapies able to modulate the efficacy of anti-cancer treatment
• In vivo/in vitro models working with delivery formulations in cancer
